Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John K Simmons

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2015
Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer TherapyAdrian M Eiden, Shuling Zhang, Joy M Gary, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|February 24, 2012
Mouse genetics 2011: meeting reportJohn K Simmons, Jessica C Amlin-Van Schaick, Thomas R Geiger, et al.
Journal of Cancer Metastasis and Treatment|September 14, 2020
Mouse tumor susceptibility genes identify drug combinations for multiple myelomaShuling Zhang, Wendy DuBois, Ke Zhang, et al.
ACS Chemical Biology|October 15, 2015
Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC ExpressionKenneth M Felsenstein, Lindsey B Saunders, John K Simmons, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinomaMatthew Kyle Labriola, Jason Zhu, Rajan T Gupta, et al.
Molecular Oncology|January 17, 2014
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasmsJohn K Simmons, Jyoti Patel, Aleksandra Michalowski, et al.
Scientific Data|April 19, 2025
Large-scale human myeloma cell line small molecule compound screen datasetV Keith Hughitt, John K Simmons, Sayeh Gorjifard, et al.
Cancer Letters|September 7, 2014
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activityOliver Ou, Konrad Huppi, Sirisha Chakka, et al.
Nature Communications|October 14, 2018
Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplexDavid R Calabrese, Xiang Chen, Elena C Leon, et al.
Molecular Cancer Therapeutics|May 20, 2017
Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC DegradationJohn K Simmons, Aleksandra M Michalowski, Benjamin J Gamache, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2015
Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer TherapyAdrian M Eiden, Shuling Zhang, Joy M Gary, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|February 24, 2012
Mouse genetics 2011: meeting reportJohn K Simmons, Jessica C Amlin-Van Schaick, Thomas R Geiger, et al.
Journal of Cancer Metastasis and Treatment|September 14, 2020
Mouse tumor susceptibility genes identify drug combinations for multiple myelomaShuling Zhang, Wendy DuBois, Ke Zhang, et al.
ACS Chemical Biology|October 15, 2015
Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC ExpressionKenneth M Felsenstein, Lindsey B Saunders, John K Simmons, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinomaMatthew Kyle Labriola, Jason Zhu, Rajan T Gupta, et al.
Molecular Oncology|January 17, 2014
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasmsJohn K Simmons, Jyoti Patel, Aleksandra Michalowski, et al.
Scientific Data|April 19, 2025
Large-scale human myeloma cell line small molecule compound screen datasetV Keith Hughitt, John K Simmons, Sayeh Gorjifard, et al.
Cancer Letters|September 7, 2014
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activityOliver Ou, Konrad Huppi, Sirisha Chakka, et al.
Nature Communications|October 14, 2018
Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplexDavid R Calabrese, Xiang Chen, Elena C Leon, et al.
Molecular Cancer Therapeutics|May 20, 2017
Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC DegradationJohn K Simmons, Aleksandra M Michalowski, Benjamin J Gamache, et al.
Pageof 2